Myriad Genetics, Inc. announced MyRisk®? Hereditary Cancer Test--the gold standard in germline testing-- has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®?) and guidelines from American Society of Clinical Oncology (ASCO). These genes are strongly associated with cancer risk and may have clear clinical actionability, supporting the goal that each addition to the panel provides meaningful insights for patient care.
The updated MyRisk panel now includes 63 carefully selected genes across more than 11 cancer types, reflecting Myriad's commitment to meeting evolving clinical needs. The MyRisk Test is designed to deliver clinical value at every step of the cancer care continuum by helping treatment decisions, surveillance planning, and family risk assessment across multiple cancer types. Clinicians can conveniently order, receive, and review expanded MyRisk Test results directly through paper Test Requisition Forms and reports, the Myriad patient portal and several electronic medical record platforms, including EPIC and OncoEMR.
